2714414-11-4
Chemical Structure
Practolol-d7
- CAS No.: 2714414-11-4
- Formula:C14H15D7N2O3
- Molecular Weight:273.38
IUPAC Name: N-(4-(2-hydroxy-3-((propan-2-yl-d7)amino)propoxy)phenyl)acetamide
InChIKey: DURULFYMVIFBIR-SVMCCORHSA-N
SMILES: CC(NC1=CC=C(OCC(O)CNC([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])C=C1)=O
Biological Activity: Practolol-d7 is the deuterium labeled Practolol. Practolol is a potent and selective β1-adrenergic receptor antagonist. Practolol can be used for the research of cardiac arrhythmias[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Practolol-d7 | Practolol-d7 is the deuterium labeled Practolol. Practolol is a potent and selective β1-adrenergic receptor antagonist. Practolol can be used for the research of cardiac arrhythmias. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Practolol (Standard) | ≥98% | Practolol (Standard) is the analytical standard of Practolol. This product is intended for research and analytical applications. Practolol is a potent and selective β1-adrenergic receptor antagonist. Practolol can be used for the research of cardiac arrhythmias. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Practolol | 99.80% | Practolol is a potent and selective β1-adrenergic receptor antagonist. Practolol can be used for the research of cardiac arrhythmias. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Iakovidis D, et, al. In vitro activity of RO363, a beta1-adrenoceptor selective agonist. Br J Pharmacol. 1980 Apr;68(4):677-85. [Content Brief]
- [3]. Adashi EY, et, al. Stimulation of beta 2-adrenergic responsiveness by follicle-stimulating hormone in rat granulosa cells in vitro and in vivo. Endocrinology. 1981 Jun;108(6):2170-8. [Content Brief]